Vioxx Re-Approval Standards Outlined In FDA Memo

Merck will need to address FDA's concerns that rofecoxib may be associated with a higher risk for cardiovascular events, the agency says in a memo outlining rationale on COX-2 inhibitors. Additional advisory committee review would be needed to consider Vioxx-specific regulatory options, FDA says.